Rationale and objectives: Gadofosveset trisodium is a blood-pool contrast agent (BPA) that shows a less pronounced r1 relaxivity advantage over gadobenate dimeglumine at 3T than at 1.5T. However, there are few data on image quality during first-pass imaging of the thoracic vasculature with gadofosveset trisodium at 3 T. Therefore, it was the aim of this study to compare first-pass imaging characteristics of gadofosveset trisodium to gadobenate dimeglumine during time-resolved contrast-enhanced three-dimensional magnetic resonance angiography (CE MRA) at 3 T.
Materials and methods: Twenty volunteers underwent time-resolved CE MRA on a 3 T magnetic resonance (MR) system with a standard eight-channel phased-array surface coil, receiving either gadofosveset trisodium (blood pool agent [BPA], n = 10) or gadobenate dimeglumine (standard contrast agent, [SCA], n = 10). Image quality was assessed by two independent readers using a Likert scale ranging from 0 = poor quality to 3 = excellent quality, and relative signal-to-noise and contrast-to-noise ratios were calculated.
Results: Equally good to excellent first-pass image quality was confirmed for time-resolved CE MRA using BPA and SCA (arteries, 2.8 ± 0.2 and 2.6 ± 0.4; veins, 2.5 ± 0.3 and 2.2 ± 0.4; artifacts, 2.4 ± 0.2 and 2.3 ± 0.1). Signal-to-noise and contrast-to-noise ratios showed nonsignificant differences, except for left subclavian artery values. There was an overall nonsignificant superiority in signal-to-noise and contrast-to-noise ratios for standard contrast agent in arterial values and BPA regarding venous values.
Conclusions: Despite a markedly decreased r1/r2 relaxivity ratio, first-pass imaging characteristics of gadofosveset trisodium and gadobenate dimeglumine are equally well suited for first pass time-resolved CE MRA at 3 T.
Copyright © 2010 AUR. Published by Elsevier Inc. All rights reserved.